Lobe Sciences Stock Performance
| LOBEF Stock | USD 0 0.0005 23.81% |
Lobe Sciences holds a performance score of 22 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 58.59, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Lobe Sciences will likely underperform. Use Lobe Sciences treynor ratio, expected short fall, and the relationship between the jensen alpha and potential upside , to analyze future returns on Lobe Sciences.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Lobe Sciences are ranked lower than 22 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile technical and fundamental indicators, Lobe Sciences reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 1.1 M | |
| Free Cash Flow | -2.7 M |
Lobe |
Lobe Sciences Relative Risk vs. Return Landscape
If you would invest 2.34 in Lobe Sciences on December 17, 2024 and sell it today you would lose (2.08) from holding Lobe Sciences or give up 88.89% of portfolio value over 90 days. Lobe Sciences is currently producing 73.828% returns and takes up 256.5444% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Lobe, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Lobe Sciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lobe Sciences' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Lobe Sciences, and traders can use it to determine the average amount a Lobe Sciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2878
| Best Portfolio | Best Equity | LOBEF | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 256.54 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.29 actual daily | 22 78% of assets perform better |
Based on monthly moving average Lobe Sciences is performing at about 22% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lobe Sciences by adding it to a well-diversified portfolio.
Lobe Sciences Fundamentals Growth
Lobe OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Lobe Sciences, and Lobe Sciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lobe OTC Stock performance.
| Return On Equity | -2.8 | |||
| Return On Asset | -0.65 | |||
| Current Valuation | (6.77 M) | |||
| Shares Outstanding | 76.97 M | |||
| Price To Earning | 1.34 X | |||
| Price To Book | 0.76 X | |||
| Price To Sales | 7.72 X | |||
| EBITDA | (4.11 M) | |||
| Cash And Equivalents | 1.38 M | |||
| Cash Per Share | 0.04 X | |||
| Book Value Per Share | 0 X | |||
| Cash Flow From Operations | (2.73 M) | |||
| Earnings Per Share | (0.31) X | |||
| Total Asset | 1.75 M | |||
About Lobe Sciences Performance
By analyzing Lobe Sciences' fundamental ratios, stakeholders can gain valuable insights into Lobe Sciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Lobe Sciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Lobe Sciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences is traded on OTC Exchange in the United States.Things to note about Lobe Sciences performance evaluation
Checking the ongoing alerts about Lobe Sciences for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Lobe Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lobe Sciences is way too risky over 90 days horizon | |
| Lobe Sciences has some characteristics of a very speculative penny stock | |
| Lobe Sciences appears to be risky and price may revert if volatility continues | |
| Lobe Sciences has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (12.25 M) with profit before overhead, payroll, taxes, and interest of 841.56 K. | |
| Lobe Sciences has accumulated about 1.38 M in cash with (2.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Lobe Sciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lobe Sciences' stock is overvalued or undervalued compared to its peers.
- Examining Lobe Sciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lobe Sciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lobe Sciences' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Lobe Sciences' otc stock. These opinions can provide insight into Lobe Sciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Lobe OTC Stock analysis
When running Lobe Sciences' price analysis, check to measure Lobe Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lobe Sciences is operating at the current time. Most of Lobe Sciences' value examination focuses on studying past and present price action to predict the probability of Lobe Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lobe Sciences' price. Additionally, you may evaluate how the addition of Lobe Sciences to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |